HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Uric acid and the prediction models of tumor lysis syndrome in AML.

Abstract
We investigated the ability of serum uric acid (SUA) to predict laboratory tumor lysis syndrome (LTLS) and compared it to common laboratory variables, cytogenetic profiles, tumor markers and prediction models in acute myeloid leukemia patients. In this retrospective study patients were risk-stratified for LTLS based on SUA cut-off values and the discrimination ability was compared to current prediction models. The incidences of LTLS were 17.8%, 21% and 62.5% in the low, intermediate and high-risk groups, respectively. SUA was an independent predictor of LTLS (adjusted OR 1.12, CI95% 1.0-1.3, p = 0.048). The discriminatory ability of SUA, per ROC curves, to predict LTLS was superior to LDH, cytogenetic profile, tumor markers and the combined model but not to WBC (AUCWBC 0.679). However, in comparisons between high-risk SUA and high-risk WBC, SUA had superior discriminatory capability than WBC (AUCSUA 0.664 vs. AUCWBC 0.520; p <0.001). SUA also demonstrated better performance than the prediction models (high-risk SUAAUC 0.695, p<0.001). In direct comparison of high-risk groups, SUA again demonstrated superior performance than the prediction models (high-risk SUAAUC 0.668, p = 0.001) in predicting LTLS, approaching that of the combined model (AUC 0.685, p<0.001). In conclusion, SUA alone is comparable and highly predictive for LTLS than other prediction models.
AuthorsA Ahsan Ejaz, Negiin Pourafshar, Rajesh Mohandas, Bryan A Smallwood, Richard J Johnson, Jack W Hsu
JournalPloS one (PLoS One) Vol. 10 Issue 3 Pg. e0119497 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID25775138 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Biomarkers
  • Uric Acid
Topics
  • Acute Kidney Injury (epidemiology, etiology)
  • Antineoplastic Agents (adverse effects)
  • Biomarkers (blood)
  • Female
  • Humans
  • Incidence
  • Leukemia, Myeloid, Acute (blood, drug therapy, genetics)
  • Male
  • Middle Aged
  • Models, Theoretical
  • ROC Curve
  • Retrospective Studies
  • Risk Factors
  • Tumor Lysis Syndrome (diagnosis, epidemiology, etiology)
  • Uric Acid (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: